Literature DB >> 16024591

Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).

Christine T Ong1, Chinedum P Babalola, Charles H Nightingale, David P Nicolau.   

Abstract

OBJECTIVES: To evaluate the penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).
METHODS: PMNs were isolated from fresh whole blood and tested for viability and purity prior to use. Tigecycline drug uptake was evaluated by incubating 5 x 10(6) cells/mL at 37 degrees C up to 3 h at tigecycline concentrations of 1, 2, 5 and 10 mg/L. Drug efflux from PMNs was determined following a 2 h incubation with tigecycline at 10 mg/L. Its intracellular activity against Staphylococcus aureus was evaluated following tigecycline extracellular exposures of 1 mg/L.
RESULTS: Tigecycline uptake was rapid and achieved high concentrations within PMNs with maximal penetration noted at 1 h of incubation. At 1 h, dose-dependent intracellular concentrations ranged from 15.83 +/- 11.09 mg/L to 264 +/- 54.60 mg/L at tigecycline 1 and 10 mg/L, respectively. At these exposures, intracellular drug concentrations were approximately 20 and 30 times higher at 1 h than extracellular concentrations. By 3 h, tigecycline displayed sustained high intracellular exposures. Tigecycline cell efflux followed first order kinetics with a half-life of 1.39 h. Tigecycline was bacteriostatic against intracellular S. aureus.
CONCLUSIONS: Tigecycline rapidly achieved high intracellular concentrations in PMNs and exhibited static activity against S. aureus supporting its potential clinical utilization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024591     DOI: 10.1093/jac/dki260

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.

Authors:  Hung-Jen Tang; Wen-Chien Ko; Chi-Chung Chen; Po-Lin Chen; Han Siong Toh; Tzu Chieh Weng; Wen-Liang Yu; Shyh-Ren Chiang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

Review 3.  Tigecycline: in community-acquired pneumonia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Bénédicte Fleury; Asllan Gjinovci; Elzbieta Huggler; Manuela Tangomo-Bento; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

5.  In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  April Barbour; Stephan Schmidt; Benjamin Ma; Lars Schiefelbein; Kenneth H Rand; Olaf Burkhardt; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.

Authors:  K S Estes; Hartmut Derendorf
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

8.  Efflux Pump Overexpression Contributes to Tigecycline Heteroresistance in Salmonella enterica serovar Typhimurium.

Authors:  Yi Chen; Daxing Hu; Qijing Zhang; Xiao-Ping Liao; Ya-Hong Liu; Jian Sun
Journal:  Front Cell Infect Microbiol       Date:  2017-02-17       Impact factor: 5.293

Review 9.  Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections.

Authors:  Nor Fadhilah Kamaruzzaman; Sharon Kendall; Liam Good
Journal:  Br J Pharmacol       Date:  2016-12-07       Impact factor: 8.739

10.  In Vitro Activity of Tigecycline Against Orientia tsutsugamushi.

Authors:  Sun Myoung Lee; Hae Yoon Kwon; Jae Hyoung Im; Ji Hyeon Baek; Seung Sik Hwang; Jae Seung Kang; Moon Hyun Chung; Jin Soo Lee
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.